S Trabelsi1, N Mama2, M Ladib3, N Karmeni3, M Haddaji Mastouri4, M Chourabi4, M Mokni5, K Tlili2, H Krifa3, M T Yacoubi5, A Saad4, D H'mida Ben Brahim4. 1. Laboratory of Cytogenetics, Molecular Genetics and Reproductive Biology, Farhat Hached University Hospital, Street Ibn Eljazzar, 4000, Sousse, Tunisia. tsaoussen@yahoo.fr. 2. Department of Imagery, Sahloul University Hospital, Sousse, Tunisia. 3. Department of Neurosurgery, Sahloul University Hospital, Sousse, Tunisia. 4. Laboratory of Cytogenetics, Molecular Genetics and Reproductive Biology, Farhat Hached University Hospital, Street Ibn Eljazzar, 4000, Sousse, Tunisia. 5. Department of Cytopathology, Farhat Hached University Hospital, Sousse, Tunisia.
Abstract
PURPOSE: The MGMT gene encodes a DNA repair enzyme that counteracts with chemotherapy efficiency, specifically with alkylating agents such as temozolomide (TMZ). It is well established that MGMT methylation should be screened as a predictive marker for TMZ in glioblastoma, and we thus aimed to determine a reliable and practical diagnostic method of MGMT methylation detection. PATIENTS AND METHODS: 55 glioblastomas were investigated for MGMT methylation status using methylation-specific multiplexed ligation probe amplification (MS-MLPA), illumina human methylation 450K BeadChip array (HM450 K) analysis, and compared to MGMT protein expression by immunohistochemistry (IHC) staining. The methylation status of promoter, intron and all MGMT CpG targeted sites were separately correlated to patient's survival. RESULTS: In addition to MS-MLPA and 450 K concordance, our results showed significantly higher overall survival (OS) of patients receiving TMZ and presenting MGMT methylated promoter (mean OS = 21.5 months, p = 0.046). Including all glioblastoma cases and regardless of chemotherapy, MS-MLPA showed significant survival difference between MGMT methylated and unmethylated cases (mean OS = 13, p = 0.021). CONCLUSION: We concluded that in glioblastoma, MGMT promoter methylation predicts TMZ sensitivity. This current comparative analysis leads to consider that MS-MLPA is a valuable as HM450 K array for MGMT methylation status screening.
PURPOSE: The MGMT gene encodes a DNA repair enzyme that counteracts with chemotherapy efficiency, specifically with alkylating agents such as temozolomide (TMZ). It is well established that MGMT methylation should be screened as a predictive marker for TMZ in glioblastoma, and we thus aimed to determine a reliable and practical diagnostic method of MGMT methylation detection. PATIENTS AND METHODS: 55 glioblastomas were investigated for MGMT methylation status using methylation-specific multiplexed ligation probe amplification (MS-MLPA), illumina human methylation 450K BeadChip array (HM450 K) analysis, and compared to MGMT protein expression by immunohistochemistry (IHC) staining. The methylation status of promoter, intron and all MGMT CpG targeted sites were separately correlated to patient's survival. RESULTS: In addition to MS-MLPA and 450 K concordance, our results showed significantly higher overall survival (OS) of patients receiving TMZ and presenting MGMT methylated promoter (mean OS = 21.5 months, p = 0.046). Including all glioblastoma cases and regardless of chemotherapy, MS-MLPA showed significant survival difference between MGMT methylated and unmethylated cases (mean OS = 13, p = 0.021). CONCLUSION: We concluded that in glioblastoma, MGMT promoter methylation predicts TMZ sensitivity. This current comparative analysis leads to consider that MS-MLPA is a valuable as HM450 K array for MGMT methylation status screening.
Entities:
Keywords:
HM450 K beadchip array; MGMT; MS-MLPA; Methylation
Authors: Pierre Bady; Davide Sciuscio; Annie-Claire Diserens; Jocelyne Bloch; Martin J van den Bent; Christine Marosi; Pierre-Yves Dietrich; Michael Weller; Luigi Mariani; Frank L Heppner; David R Mcdonald; Denis Lacombe; Roger Stupp; Mauro Delorenzi; Monika E Hegi Journal: Acta Neuropathol Date: 2012-07-19 Impact factor: 17.088
Authors: Shuji Ogino; Jeffrey A Meyerhardt; Takako Kawasaki; Jeffrey W Clark; David P Ryan; Matthew H Kulke; Peter C Enzinger; Brian M Wolpin; Massimo Loda; Charles S Fuchs Journal: Virchows Arch Date: 2007-03-20 Impact factor: 4.064
Authors: M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman Journal: N Engl J Med Date: 2000-11-09 Impact factor: 91.245
Authors: K K Herfarth; T P Brent; R P Danam; J S Remack; I J Kodner; S A Wells; P J Goodfellow Journal: Mol Carcinog Date: 1999-02 Impact factor: 4.784
Authors: Martin J van den Bent; Hendrikus J Dubbink; Marc Sanson; Cathleen R van der Lee-Haarloo; Monika Hegi; Judith W M Jeuken; Ahmed Ibdaih; Alba A Brandes; Martin J B Taphoorn; Marc Frenay; Denis Lacombe; Thierry Gorlia; Winand N M Dinjens; Johan M Kros Journal: J Clin Oncol Date: 2009-11-09 Impact factor: 44.544
Authors: Judith W M Jeuken; Sandra J B Cornelissen; Martine Vriezen; Marieke M G Dekkers; Abdellatif Errami; Angelique Sijben; Sandra H E Boots-Sprenger; Pieter Wesseling Journal: Lab Invest Date: 2007-08-13 Impact factor: 5.662
Authors: Rosa Della Monica; Mariella Cuomo; Michela Buonaiuto; Davide Costabile; Raduan Ahmed Franca; Marialaura Del Basso De Caro; Giuseppe Catapano; Lorenzo Chiariotti; Roberta Visconti Journal: Int J Mol Sci Date: 2022-06-27 Impact factor: 6.208
Authors: Daniel J Brat; Kenneth Aldape; Julia A Bridge; Peter Canoll; Howard Colman; Meera R Hameed; Brent T Harris; Eyas M Hattab; Jason T Huse; Robert B Jenkins; Dolores H Lopez-Terrada; William C McDonald; Fausto J Rodriguez; Lesley H Souter; Carol Colasacco; Nicole E Thomas; Michelle Hawks Yount; Martin J van den Bent; Arie Perry Journal: Arch Pathol Lab Med Date: 2022-05-01 Impact factor: 5.686
Authors: Alireza Mansouri; Laureen D Hachem; Sheila Mansouri; Farshad Nassiri; Normand J Laperriere; Daniel Xia; Neal I Lindeman; Patrick Y Wen; Arnab Chakravarti; Minesh P Mehta; Monika E Hegi; Roger Stupp; Kenneth D Aldape; Gelareh Zadeh Journal: Neuro Oncol Date: 2019-02-14 Impact factor: 12.300
Authors: Alexandra McAleenan; Claire Kelly; Francesca Spiga; Ashleigh Kernohan; Hung-Yuan Cheng; Sarah Dawson; Lena Schmidt; Tomos Robinson; Sebastian Brandner; Claire L Faulkner; Christopher Wragg; Sarah Jefferies; Amy Howell; Luke Vale; Julian P T Higgins; Kathreena M Kurian Journal: Cochrane Database Syst Rev Date: 2021-03-12